Vitamin D3 as a novel regulator of basic fibroblast growth factor in chronic rhinosinusitis with nasal polyposis.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this controlled clinical trial publication.

This study investigated the correlation between plasma 25-VD3 and sinonasal mucus monocyte chemoattractant protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted (RANTES), and basic fibroblast growth factor (bFGF) levels in patients with CRS.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Study subjects undergoing endoscopic sinus surgery (ESS) for CRS were prospectively enrolled from January 2012 to August 2014.

Control subjects included patients undergoing ESS for noninflammatory pathology.

How the Study Was Run

Blood and sinonasal mucus were collected at the time of ESS.

Plasma 25-VD3 was measured by enzyme-linked immunosorbent assay (ELISA) and mucus levels of MCP-1, RANTES, and bFGF by cytometric bead array (CBA).

What Was Measured

This study investigated the correlation between plasma 25-VD3 and sinonasal mucus monocyte chemoattractant protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted (RANTES), and basic fibroblast growth factor (bFGF) levels in patients with CRS.

The subject headings attached to it are Chemokine CCL2, Chemokine CCL5, Cholecalciferol, Chronic Disease, Endoscopy, Fibroblast Growth Factor 2 and Fibroblasts.

The authors tagged it with the keywords 25-dihydroxyvitamin D3, fibroblast growth factor-2, polyps, sinusitis and vitamin D.

What This Means in Plain Language

This is a controlled clinical trial of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (International forum of allergy & rhinology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.